Resistance Training, Myostatin, and Sarcopenia: What Changes

Resistance training can lower myostatin—a protein that restrains muscle growth—in older adults with sarcopenia. The effect is modest, and the best available analysis does not show the same response in frail older adults. That distinction matters: sarcopenia and frailty often overlap, but they are not interchangeable diagnoses or necessarily the same biological problem.

Myostatin belongs to the TGF-β family and acts as a negative regulator of skeletal muscle mass. Higher circulating levels have been reported in older adults with sarcopenia and frailty. That makes it an appealing target, especially because low muscle mass carries real stakes: a 2021 systematic review and meta-analysis found that older adults who died during follow-up had lower appendicular skeletal muscle mass index than survivors (standardized mean difference [SMD] −0.18, 95% CI −0.23 to −0.12). This is an association, not proof that raising muscle mass or lowering myostatin will prevent death. Still, preserving muscle and function is a reasonable clinical priority.

Resistance training moves the biomarker a little

A 2026 systematic review and meta-analysis by Chu et al. pooled nine randomized controlled trials, covering 11 intervention arms and 330 frail and/or sarcopenic older adults. Participants completed at least eight weeks of resistance training, and the outcome was serum myostatin.

Across all groups combined, resistance training was associated with a small reduction in serum myostatin: SMD −0.23 (95% CI −0.44 to −0.01; I²=0%). The confidence interval only barely excludes zero. That makes this a statistically marginal signal, not a result to build a supplement aisle around. The authors rated the certainty of the evidence as very low.

The more informative finding came from the diagnosis-specific analyses. In older adults with sarcopenia, resistance training reduced serum myostatin by SMD −0.35 (95% CI −0.65 to −0.06; p<0.05). By conventional effect-size labels, that falls between small and moderate. It shows that resistance training can engage this pathway in sarcopenic adults. It does not show how much muscle mass, grip strength, walking speed, or independence a person gains from that biomarker change.

That missing link is the central restraint on the claim. Chu et al. analyzed serum myostatin, not DXA-measured muscle mass, gait speed, grip strength, or Short Physical Performance Battery scores as co-primary outcomes. A lower myostatin value is a surrogate endpoint. Biology is useful; it is not a discharge summary.

Frailty did not show the same response

Among frail older adults, the estimated effect was SMD −0.08 (95% CI −0.40 to 0.23; p=0.599). This result was not statistically significant, and the interval allows both a modest decrease and a modest increase. The difference between the sarcopenia and frailty subgroup estimates reached statistical significance (p<0.05), but the small evidence base makes any subgroup conclusion fragile.

The result still fits a clinically sensible model. Sarcopenia is defined by deficits in muscle mass and/or strength. Frailty is broader: it can involve malnutrition, inflammation, cumulative cellular damage, cognitive decline, and reduced physical reserve. Resistance training may help frail adults for several reasons, but current evidence does not support treating myostatin suppression as the pathway through which it reliably helps them.

That is why a broader plan makes more sense for frailty. A 2021 meta-analysis of resistance training plus nutritional interventions examined muscle mass, strength, and physical function in older adults, while a 2024 review of multidomain interventions evaluated physical and cognitive approaches in older adults. Neither study proves that a particular program corrects frailty's biology, but both support looking beyond one biomarker and one intervention.

A plausible mechanism, not a complete explanation

Resistance exercise may suppress myostatin activity through decorin, a small protein released by contracting muscle that can bind myostatin outside the cell. In a 2022 randomized trial in healthy aged women, progressive resistance training was studied with and without L-carnitine plus leucine supplementation. The work supports decorin as a plausible link between training and myostatin activity; adding L-carnitine and leucine did not improve the training effect on that pathway.

Plausibility is not proof that decorin explains the sarcopenia subgroup result, nor does it establish why the frailty subgroup did not respond. Frailty may create a more catabolic environment in which changing one signal does not shift the overall balance. That remains a hypothesis rather than a demonstrated mechanism from the pooled trials.

Training works even if myostatin is not the scoreboard

The practical case for resistance training does not rest on myostatin alone. A 2024 meta-analysis by Sun et al. included 22 randomized controlled trials and 959 sarcopenic older adults and found that resistance training improved body composition, muscle strength, and biomarkers. Those functional and body-composition outcomes matter more to patients than a blood marker.

Nutrition may add something, though the certainty is not high. A 2026 review of resistance training plus amino acid-based supplementation in sarcopenic older adults found low- to very-low-certainty evidence of added benefit over training alone for some outcomes. The included supplements were essential amino acids, branched-chain amino acids, leucine, and HMB. This does not mean every older lifter needs a leucine tub on the counter; it means inadequate dietary intake deserves attention when clinicians assess sarcopenia.

A Mediterranean-style dietary pattern may also help address diet quality and inflammation, but evidence specific to myostatin response is absent. A 2025 review of Mediterranean diet studies in musculoskeletal disorders reported possible benefits related to musculoskeletal disease risk and progression, not proof that the diet lowers myostatin in frail adults.

Why the estimate remains uncertain

Small meta-analyses can look tidier than they are. Chu et al. reported I²=0%, but 11 intervention arms provide limited power to detect genuine differences between studies. The trials also used different diagnostic criteria for sarcopenia and frailty, including EWGSOP, AWGS, Fried phenotype, and FRAIL-scale approaches. Those criteria can identify people at different stages and with different mixes of muscle loss and systemic illness.

The review did not provide a usable dose-response answer for myostatin. It did not systematically establish which resistance-training intensity, volume, weekly frequency, or duration produced the subgroup effect. Eight weeks was the minimum intervention duration, not a prescription for the optimal program. The study also cannot calibrate its SMD values against the size of age-related myostatin changes across the lifespan.

Older adults using GLP-1 receptor agonists deserve separate study. A 2025 systematic review described ongoing debate about GLP-1 drugs and sarcopenia-related markers in diabetes, including concern about lean-mass loss during weight reduction. The resistance-training/myostatin trials did not establish how these medications alter the response. Monitoring muscle mass and strength is sensible clinical practice, but no trial here shows that resistance training offsets medication-related lean-mass changes through myostatin.

For sarcopenic older adults, resistance training has a small, statistically significant association with lower serum myostatin after at least eight weeks. For frail older adults, the current pooled estimate does not show that effect.

The useful conclusion

Myostatin is a credible part of aging-muscle biology, but it is not yet a practical dial for personal optimization. The strongest direct finding is modest myostatin suppression in sarcopenic older adults, based on a small body of very-low-certainty evidence. Resistance training remains worthwhile because randomized-trial syntheses show improvements in strength and body composition in sarcopenia. Myostatin helps explain part of that story; it does not replace assessment of strength, function, nutrition, comorbidities, and frailty.

For an older adult with confirmed sarcopenia, supervised, progressive resistance training is the evidence-based starting point. For someone who is frail, the same training may still belong in the plan, but it should sit inside a broader evaluation of nutrition, physical function, cognition, medical conditions, and support needs. A serum marker can be interesting. Getting out of a chair, carrying groceries, and avoiding a fall are the outcomes that count.